Active Recombinant Human GZMB, His tagged

• Cat.No.: GZMB-296H
• Product Overview: Recombinant Human GZMB proform (NP_004122.1) (Met 1-Tyr 247), fused with a C-terminal polyhistidine tag, was produced in HEK293 Cells.

Specification

• Source: HEK293
• Species: Human
• Tag: His
• Form: Lyophilized from sterile PBS, pH 7.4.
  Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured by its ability to cleave a peptide substrate, tButyloxycaronylAlaAlaAspThioBenzylester (BocAADSBzl),in the presence of 5,5’Dithiobis (2nitrobenzoic acid) (DTNB). The specific activity is >1500 pmol/min/μg. (The enzyme needs to be activated by Recombinant Mouse Active Cathepsin C)
• Molecular Mass: The recombinant human Granzyme B consists of 240 amino acids and has a calculated molecular mass of 27.2 kDa. As a result of glycosylation, the apparent molecular mass of rhGranzyme B is approximately 35-40 kDa in SDS-PAGE under reducing conditions.
• Protein length: Met 1-Tyr 247
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: ≥ 97 % as determined by SDS-PAGE ≥ 95 % as determined by SEC-HPLC.
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C
  Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4℃ before opening to recover the entire contents.

Gene Information

• Gene Name: GZMB granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1) [ Homo sapiens ]
• Official Symbol: GZMB
• Synonyms: GZMB; granzyme B (granzyme 2, cytotoxic T-lymphocyte-associated serine esterase 1); CSPB, CTLA1; granzyme B; cathepsin G like 1; CCPI; CGL 1; CGL1; CSP B; CTSGL1; cytotoxic serine protease B; fragmentin 2; HLP; SECT; T cell serine protease 1 3E; C11; CTLA-1; fragmentin-2; cathepsin G-like 1; human lymphocyte protein; T-cell serine protease 1-3E; cytotoxic T-lymphocyte proteinase 2; CSPB; CGL-1; CSP-B; CTLA1
• Gene ID: 3002
• mRNA Refseq: NM_004131
• Protein Refseq: NP_004122
• MIM: 123910
• UniProt ID: P10144

Reviews

11/01/2020

I am delighted to express my complete satisfaction with the quality of GZMB protein, as it precisely suits my experimental requirements.

08/29/2017

Their knowledgeable team has been readily available to address any concerns or queries, providing effective solutions and guidance whenever needed.

07/28/2017

I have full confidence in the GZMB protein and the exceptional support provided by the manufacturer, making it my top recommendation for researchers seeking a high-quality protein for their experimental needs.

Q&As

What are some potential future applications of GZMB in medicine?

GZMB may be used in the development of targeted therapies for viral infections and various immune-related disorders.

How is GZMB protein clinically relevant in cancer treatment?

GZMB can be used in cancer immunotherapy to target and eliminate cancer cells.

What are the challenges in using GZMB in cancer immunotherapy?

One challenge is to ensure that GZMB selectively targets cancer cells without causing harm to healthy cells.

What types of cancer can be targeted using GZMB-based therapies?

GZMB-based therapies can be used against various types of cancer, including leukemia, lymphoma, and solid tumors.

Can GZMB be used in autoimmune disease treatment?

GZMB's role in autoimmune diseases is complex. It can contribute to tissue damage in some autoimmune conditions, but its use in treatment is not common.